LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:40 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:40 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Zacks News
Acadia Healthcare Expands Behavioral Health Services in Iowa
by Zacks Equity Research
ACHC breaks ground on a new behavioral health hospital in Council Bluffs, addressing regional care shortages through a joint venture with Methodist Health System.
Ensign Group (ENSG) Up 50% in Past Year: More Growth on the Horizon?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of improved skilled services revenues, higher rental revenues and adequate operating cash flows.
Why You Should Add HCA Healthcare (HCA) to Your Portfolio Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on growing emergency room visits, buyouts and solid cash flows.
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stock to Buy for August 6th
by Zacks Equity Research
HWKN, PPC and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 6, 2024.
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 10.64% and 1.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
HLN vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HLN vs. LMAT: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
by Zacks Equity Research
Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.
GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.
Encompass Health (EHC) Gains 30% in a Year: More Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of sustained top-line growth, an aging U.S. population, frequent expansion initiatives and strong cash reserves.
LeMaitre (LMAT) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for June 21st
by Zacks Equity Research
ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.
Compelling Reasons to Hold on to Ensign Group (ENSG) Stock
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, an expanding healthcare portfolio and solid cash reserves.
UnitedHealth Unit (UNH) Wins Medicaid Deal to Serve Kansas
by Zacks Equity Research
UnitedHealth Group (UNH) receives a contract from the State of Kansas to provide enhanced care to beneficiaries of the KanCare program and gain a greater Medicaid customer base.
All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy
by Zacks Equity Research
LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why You Should Add Encompass Health (EHC) to Your Portfolio Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 12.82% and 3.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
by Zacks Equity Research
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
by Zacks Equity Research
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.